Please ensure Javascript is enabled for purposes of website accessibility

3 Growth Stocks Under $50 That Could Double Your Money

By Keith Speights – Sep 5, 2021 at 6:01AM

Key Points

  • One is a leader in the rapidly expanding U.S. cannabis market.
  • Another is a potential game-changer in diagnosing skin cancer.
  • The third is an up-and-coming fintech platform provider with excellent growth prospects.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You won't need much upfront cash to buy these promising growth stocks.

Lots of investments can double your money. Some of them require huge amounts of upfront cash. Many also require a long time to provide that 100% return you want.

There are some investment alternatives, though, that don't need a hefty initial amount and don't take an agonizingly slow period to grow. Here are three stocks you can buy for under $50 each that could realistically double your money over the next five years.

Two smiling people sitting on a sofa and looking at a laptop.

Image source: Getty Images.

Cresco Labs

You might have a negative mental picture when you think of cannabis stocks. Many of these stocks are risky and unprofitable. Some are downright sketchy. However, Cresco Labs (CRLBF -2.35%) doesn't belong in that group.

Cresco ranks as the No. 1 cannabis wholesaler in the U.S. It's also one of the top multi-state cannabis operators with more than 30 retail locations in 10 states, including seven of the top 10 biggest markets. 

The company is profitable. Its sales soared nearly 123% year over year in the second quarter. Cresco expects to have an annualized revenue run rate of $1 billion by the end of this year. It has strong growth prospects in its current markets plus great opportunities to expand into new markets.

Cresco's share price is less than $10. The stock trades at only 2.1 times expected 2022 sales. I view Cresco as one of the best bargains in the cannabis industry.

DermTech

The term "game-changer" is probably overused these days. But DermTech (DMTK 0.84%) is one company that I believe truly deserves the description. 

DermTech markets genomic tests used to diagnose melanoma. The company's Pigmented Lesion Assay (PLA) product is 17 times less likely to miss a melanoma diagnosis than the current standard approach of surgical biopsy and histological analysis. And PLA is around 40% cheaper than the biopsy/histology method. 

The company plans to expand beyond melanoma into other skin cancers. That's important, considering that roughly one in five Americans will have skin cancer by age 70. DermTech thinks that its addressable market stands at around $10 billion, with much of that opportunity related to testing for ultraviolet ray damage and skin cancer risk. 

After falling close to 50% below its highs from earlier this year, DermTech's share price is now below $40. The stock should bounce back in a big way as more dermatologists learn about PLA and prescribe the test more frequently. 

SoFi Technologies

SoFi Technologies (SOFI -1.29%) is another stock that's been beaten down this year but still has great prospects. It offers a one-stop shop for digital financial services.

Although SoFi isn't profitable yet, the company has delivered four consecutive quarters of positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). Just as important, SoFi's membership growth is accelerating quickly, more than doubling year over year in Q2. 

SoFi continues to roll out new functionality on its app that makes obtaining loans, saving, spending, and investing easier. Its Galileo business that performs processing for other fintech platforms could even become bigger than Sofi is today

The stock costs less than $15 right now. My view is that SoFi could realistically double or more over the next five years as it transitions to profitability with its platforms.

Keith Speights owns shares of DermTech, Inc. and SoFi Technologies, Inc. The Motley Fool owns shares of and recommends Cresco Labs Inc., DermTech, Inc., and SoFi Technologies, Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

SoFi Technologies, Inc. Stock Quote
SoFi Technologies, Inc.
SOFI
$4.60 (-1.29%) $0.06
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$3.32 (-2.35%) $0.08
DermTech, Inc. Stock Quote
DermTech, Inc.
DMTK
$2.41 (0.84%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.